For WHO grade 3 and high-risk WHO grade 2 astrocytomas, adjuvant TMZ following radiotherapy is typically recommended, stemming from studies demonstrating improved outcomes compared to radiotherapy alone, particularly in IDH-mutant tumors45,46. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).